4.1 Review

Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation

Journal

ANTIVIRAL THERAPY
Volume 15, Issue -, Pages 31-35

Publisher

INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1525

Keywords

-

Funding

  1. Bristol Myers Squibb
  2. Abbott Laboratories
  3. Boehringer-Ingelheim
  4. Gilead
  5. GlaxoSmithKline
  6. Johnson Johnson
  7. MSD
  8. Pfizer
  9. Roche
  10. Schering Plough
  11. Tibotec
  12. ViiV
  13. Vertex

Ask authors/readers for more resources

Here, we present recommendations relevant to the diagnosis and management of late presentation with HIV infection, divided for convenience into four topic areas: the definition and epidemiology of late presentation, the medical and societal consequences of late presentation, earlier testing for HIV infection and the management of late presentation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available